

Covid-19: Effect on Hemostasis

Zabolotsky Dmitrii V., Koryachkin Viktor A., Puzyrev Viktor.G.

Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation.

Abstract

Since December 2019, the first cases of coronavirus infection began to be registered, by now there is enough data accumulated to analyze the pathogenesis of the disease, as well as to develop etiopathogenetic treatment. The cytokine storm and coronaviral induced coagulopathy are considered to be the main pathogenesis link, which made possible to develop an etiopathogenetic treatment. Cytokine Storm destroys precursor cells and reduces platelet production. The further formation of autoimmune complexes leads to thrombocytic destruction and induces damage to the endothelial cells of lung capillaries. Recommended direct parenteral anticoagulants treatment with low-molecular weight heparin forms (LMHs).

Keywords: COVID-19- Coronavirus- Effect on hemostasis

Asian Pac Environ Cancer, 3 (Suppl 1), 9-11

Submission Date: 06/15/2020 Acceptance Date: 07/07/2020

Introduction

In December 2019, the WHO office in China first reported an epidemic of unexplained lower respiratory tract infections in Wuhan. The disease, which belongs to the coronavirus family, is called Coronavirus Disease 2019 (COVID-19). The exponential growth of coronavirus infection has led to an increase in infections worldwide and significant mortality in a number of countries.

The pathogenesis of a new coronaviral infection is not fully investigated. The main target of the virus are type II lung alveolar cells with receptors of type II angiotensin converting enzyme. It is believed that the receptor CD147 (Basing (CD147, EMMPRIN)), a multifunctional glycoprotein in the cellular membrane, is one of the ways the virus penetrates the cell. Currently only little information is available about the interaction of the virus with erythrocyte porphyrin, leading to impaired hemoglobin-oxygen binding and hyperferritinemia. However, SARS-Cov_2-infection has been shown to be associated with coagulopathy, a complication linked to an overreaction of the immune-system.

Cytokine Storm

Much attention is paid to the “cytokine storm”, an umbrella term for an overproduction of cytokines triggered by infections, faulty genes or autoimmune

disorders, through which patients with COVID-19 show high levels of neutrophils, linked to a high risk of development of acute respiratory distress syndrome (ARDS). The severity of pulmonary infiltration depends on the degree of pulmonary invasion by neutrophils and monocytes/macrophages as well as their quantity in peripheral blood. Neutrophils produce cytokines and chemokines [1]. Thus, lymphopenia and neutrophilia are considered as blood born severity markers in patients with COVID-19, as they are predictors for a rather malign course of the infectious process [2].

COVID-19 induced coagulopathy

Along with clinical manifestations of symptoms similar to those observed with common cold, a number of specialists consider the development of coagulopathy to be an adverse outcome factor of the disease. Pulmonary tissue autopsies of patients who died from severe acute respiratory infections show microvascular lesions, occlusions and micro thrombosis mediated by complement activation and associated procoagulant status. Damage to endothelial capillary cells of lung tissue by cytokines leads to platelet activation and clotting, micro thrombosis and fibrin deposition. In some cases also skin lesions with confirmed inflammatory thrombogenic vasculopathy have

Corresponding Author:

Dr. Zabolotsky Dmitrii V.

Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation.

Email: zdv4330303@gmail.com

been reported [3]. Hypoxia further promotes thrombosis by increasing blood viscosity and by transmitting signals to hypoxia-induced factors (HIFs) [4].

Coagulation is further promoted by treatment, as patients with severe forms of COVID-19 infection requiring artificial lung ventilation are immobilized, which can cause stagnation of blood flow. Additionally, intensive therapy requires catheterization of vessels (both mainline and peripheral), which is a cause of endothelial damage.

Thrombocytopenia is generally not an indicator of increased severity, but it must be differentiated from pseudothrombocytopenia. In-vitro, anticoagulant induced auto-antibody production (by application of EDTA, ethylenediaminetetraacetic acid) induces artificial platelet coagulation, leading to incorrect thrombozyte counts. The frequency of this phenomenon is about 2%, so if pseudo thrombocytopenia is suspected, blood samples are taken in tubes containing citrates or heparin as anticoagulant, and platelet count is performed manually [5].

COVID-19 patients typically do not display significant level of true thrombocytopenia. The Yang X. et al. study included 1476 patients, of whom 238 (16.1%) died. Thrombocytopenia was observed in 306 (20.7%) patients with platelet count as the lower limit of the normal range $125 \times 10^9 / l$ [6].

The mechanisms of thrombocytopenia in patients with new coronaviral infection consist in the infection of hemopoietic cells of the bone marrow resulting in dysfunctional hemopoiesis. Cytokine Storm destroys precursor cells and reduces platelet production. The further formation of autoimmune complexes leads to thrombocytic destruction and induces damage to the endothelial cells of lung capillaries, triggering platelet activation, aggregation and reduction of circulating blood platelets [7].

Diagnostic aspects

Decrease in thrombocyte numbers can be a sign of organ dysfunction, sepsis, and the development of a disseminated intravascular clotting syndrome (ICA). Monitoring of platelet count during hospitalization is thus very important for prognosis in patients with COVID-19. Intra-hospital lethality is tripled in patients with thrombocytopenia. The lower the platelet count, the higher the mortality rate [6].

The state of hypercoagulation is confirmed by coagulogram data. The given components of Virkhov's triad testify to the propensity of this group of patients for thrombosis. One of the most common laboratory indicators studied in COVID-19 patients is the coagulogram, indicating thrombocytopenia, hyperfibrinogenemia and D-dimer increase.

Changes in coagulogram screening tests (ACTV; PV) are insignificant. Increased values of D-dimer, PDF, fibrinogen, decrease of antithrombin and PT levels measured by Quicktest were found in lethal COVID-19 patients [8]. Additional laboratory studies show an increase in the activity of anti-hemophilic factor VIII, which belongs to the proteins of the inflammatory phase, as well as an increase in von Willebrand factor, which

confirms the damage of glycocalyx of endothelial cells by cytokines [9].

A number of studies have shown efficacy of bedside methods like thromboelastography (TEG) in diagnostics of hypercoagulation [10]. However, the clinical value of TEG in COVID-19 has not yet been established [11]. In contrast, the efficacy of anticoagulant heparin therapy in patients with extra-hospital pneumonia was proven even before the pandemic of a new coronavirus infection.

Treatment of COVID-19 induced hypercoagulation

When direct parenteral anticoagulants are chosen, low-molecular weight heparin forms (LMHs) should be preferred, which have a lower molecular weight (4000 - 5000 kD) than unfractionated heparin and block factor Ha to a greater extent while less frequently causing complications such as heparin-induced thrombocytopenia and osteoporosis. Accordingly, a reduction of treatment duration in patients on artificial lung ventilation using LMH has been observed [12]. The synthetic medication fondaparinux also showed its effectiveness in reducing the total mortality and frequency of pulmonary artery thromboembolism in patients with extra-hospital pneumonia in comparison with placebo [13].

Pharmacological prevention of thromboembolic complications is required for all patients with severe COVID-19. LMH and fondaparinux do not interact with other drugs that are used in the treatment of new coronaviral infection. At present, anticoagulant dosing solutions must be specifically tailored to optimize treatment as drugs with antithrombotic effects represent also risk factors for thromboembolic complications, or bleeding [14].

Thus, in all patients with COVID-19 it is necessary to evaluate the coagulation status in dynamics by determining the level of D-dimers, prothrombin time, platelet count, fibrinogen content, as well as to prescribe low-molecular heparins for preventive purposes.

References

1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*. 2020 07 01;180(7):934. <https://doi.org/10.1001/jamainternmed.2020.0994>
2. Guidelines and features of clinical manifestations and treatment of the disease caused by a new coronavirus infection (COVID-19) in children. Version 1 (04.24.2020). Moscow, 2020. - 44 p. Available: [https://www.24042020_child_COVID-19_1_Final.pdf%20\(1\).pdf](https://www.24042020_child_COVID-19_1_Final.pdf%20(1).pdf)
3. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Translational Research*. 2020 06;220:1-13. <https://doi.org/10.1016/j.trsl.2020.04.007>
4. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe

- coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*. 2020 04 27;18(5):1094-1099. <https://doi.org/10.1111/jth.14817>
5. Payne BA, Pierre RV. Pseudothrombocytopenia: A Laboratory Artifact With Potentially Serious Consequences. *Mayo Clinic Proceedings*. 1984 02;59(2):123-125. [https://doi.org/10.1016/s0025-6196\(12\)60247-x](https://doi.org/10.1016/s0025-6196(12)60247-x)
 6. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y. Thrombocytopenia and its association with mortality in patients with COVID-19. *Journal of Thrombosis and Haemostasis*. 2020 05 04;18(6):1469-1472. <https://doi.org/10.1111/jth.14848>
 7. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients [published online ahead of print, 2020 Apr 15]. *Ann Hematol*. 2020;:1-4.
 8. Han H, Yang L, Liu R, Liu F, Wu K, Li J, Liu X, Zhu C. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2020 06 25;58(7):1116-1120. <https://doi.org/10.1515/cclm-2020-0188>
 9. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *Journal of Thrombosis and Haemostasis*. 2020 05 06;18(7):1747-1751. <https://doi.org/10.1111/jth.14854>
 10. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. *Journal of Thrombosis and Haemostasis*. 2020 06 24;18(7):1738-1742. <https://doi.org/10.1111/jth.14850>
 11. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R, Tripodi A. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis, SISET. *Blood Transfusion*. 2020 05 22; <https://doi.org/10.2450/2020.0083-20>
 12. Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of Low Molecular Weight Heparin in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2013 Oct 02;11(2):171-176. <https://doi.org/10.3109/15412555.2013.831062>
 13. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ*. 2006 01 26;332(7537):325-329. <https://doi.org/10.1136/bmj.38733.466748.7c>
 14. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology*. 2020 07;76(1):122-124. <https://doi.org/10.1016/j.jacc.2020.05.001>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.